NV103: antibody conjugated nanoparticle for ewing sarcoma targeted therapy
Ended Cooperative Agreement Awarded Last action
- Award ID
- R44CA233128
- Recipient
-
Nanovalent Pharmaceuticals Inc. UEI NFPTYA1R6KY1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,152,772
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Bozeman, MT, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $790 | |
| Amendment | $891,979 | |
| Amendment | $0 | |
| Amendment | $1,019,254 | |
| Original award | $240,749 |
Quick answers
Who received award R44CA233128?
R44CA233128 was awarded to Nanovalent Pharmaceuticals Inc. by National Cancer Institute (National Institutes of Health) on September 14, 2018.
How much is award R44CA233128 worth?
$2,152,772 has been obligated on R44CA233128.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award